JP Morgan Initiates Coverage On Day One Biopharmaceutical with Overweight Rating, Announces Price Target of $38
JP Morgan analyst Anupam Rama initiates coverage on Day One Biopharmaceutical (NASDAQ:DAWN) with a Overweight rating and announces Price Target of $38.